The current study demonstrated that the AKT inhibitor MK2206 or the mTOR inhibitor rapamycin could mitigate the stemness of gefitinib-resistant lung cancer cells and enhance their sensitivity to gefitinib by suppressing the mTOR signaling pathway. The gene discussed is AKT1; the disease is lung cancer.